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TO THE EDITOR
Omalizumab is a mAb therapeutic
directed against IgE. It is FDA (Food
and Drug Administration) approved for
use in allergic asthma (Presta et al.,
1993; Strunk and Bloomberg, 2006). It
binds IgE at the same site on its Fc
domain as the a-chain of the high–
affinity IgE receptor (FceRI) and blocks
the interaction between IgE and FceRI
on mast cells, basophils, and dendritic
cells (Presta et al., 1993; Schulman,
2001; Prussin et al., 2003). As the IgE
level decreases with omalizumab, FceRI
expression on basophils and mast cells
are reduced within 7 days for basophils
(MacGlashan et al., 1997) and within
56–70 days for skin mast cells (Beck
et al., 2004; Ong et al., 2005).
In a recent study, we found that in
cat–allergic subjects receiving omalizu-
mab, the acute–phase clinical responses
to nasal allergen challenge (NAC) were
decreased at a time when blood baso-
phils (6–8 weeks), but not nasal mast
cell–mediator responses, were depressed
(Eckman et al., 2010). This suggests that
some process, other than mast cell
secretion, has a part in defining the
acute–phase clinical responses of an
NAC response. Acute–phase skin test
suppression occurred at 14 weeks.
In this different study, we examined
the effects of omalizumab on the nose
and skin late–phase reactions at the time
of basophil, but not mast cell, hypor-
esponsiveness. The study was a 16-week,
double–blind, placebo–controlled trial
of 19 cat–allergic adult subjects, who
were randomly assigned to receive
either omalizumab or matched placebo
in a 1:1 ratio on the basis of the FDA–
approved dosing schedule for allergic
asthma.
Subjects underwent basophil hista-
mine response (BHR) and prostaglandin
D2 testing, as well as NAC as previously
described (Eckman et al., 2010) with
three separate challenges of cat allergen
(100, 300, and 1,000 BAU ml 1). Late–
phase sneeze counts were measured 4,
8, and 24 hours after NAC. Cat allergen–
titrated intradermal skin testing (IDST)
was performed at two half–log con-
centrations of allergen solution begin-
ning with either 0.1 or 0.3 BAU ml1
depending on the cat puncture skin
test result. Concentrations were then
increased until the average wheal of a
single injection was X15 mm. Late–
phase–induced skin induration was
measured at 8 and 24 hours. When a
subject’s cat allergen–induced BHR area
under the curve (AUC) decreased to
o20% of the baseline value or on study
day 56 (week 8), whichever occurred
first, a second NAC (NAC-2), IDST, and
BHR were performed.
No significant differences were pre-
sent between baseline characteristics
(age, gender, cat puncture test size, total
IgE, cat–specific IgE, and percentage
of subjects reporting mild asthma
(FEV1X80%)) in the 10 active and
9 placebo subjects who completed
the study. The IgE ranges were 53–
298 kU l1 for total IgE, and 1.0–41.5
for cat–specific IgE, for all subjects.
Specific to total IgE ratio levels fell
into the previously reported atopic
population range of 0.002–35.8% for
cat–sensitized individuals and were
maintained during omalizumab treat-
ment, as seen previously (Hamilton
et al., 2010).
The average day of NAC-2 was day
48 for treatment group and day 65 for
placebo. Consistent with our previous
study, at NAC-2, the median cat BHR
AUC showed a 57% decrease on oma-
lizumab treatment compared with a
21% increase on placebo administration
(P¼ 0.008, data not shown). As was
seen in our previous study (Eckman
et al., 2010), the acute–phase sneezes
trended toward a greater decrease from
NAC-1 in the treated group compared
with placebo. The change from baseline
for the treatment group was a median of
12 sneezes (interquartile range (IQR):
1.5–18.5), or 36%, compared with 4
sneezes (IQR:  8.5–11.5), or 4%, for
the placebo group. Within the treatment
group, the sneezes at NAC-1 were
statistically different compared with
NAC-2 (P¼0.01, two tailed). There
were no differences between or within
groups at 8 or at 24 hours (Figure 1).
Measures of nasal mast cell allergen
responses (nasal lavage PGD2) did not
change at the time of NAC-2 (data not
shown). For the late–phase nasal reac-
tion, of the 74% of subjects who had
late–phase sneezes recorded, no signifi-
cant change from baseline was seen in
the omalizumab treatment group com-
pared with placebo.
IDST flares were similar between
groups at baseline at all time points
during the baseline NAC-1. The acute
skin flare size at NAC-1 was 134.0 mm
(IQR: 119.8–146.5) for treatment group
and 112.0 mm (IQR: 103.0–136.0) for
placebo. There was no difference in
acute skin flare changes at NAC-2
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between treated and placebo groups. At
8 hours, the flare size decreased from
NAC-1 to NAC-2 by 52.3 mm (IQR:
27.8–101.4, 54% decrease) in the treat-
ment group, compared with 0 mm (IQR:
 6.0–7.3) in the placebo group
(P¼ 0.008, two tailed). At 24 hours, the
flare size decreased by 9.3 mm (IQR: 0–
48.3, 38% decrease) in the treatment
group, compared with an increase of 1.5
(1.5) mm (IQR:  7.0–9.3) for the
placebo group (10% decrease, Figure 1).
The skin late–phase response decrease
at day 48 (range of 27–69 days) is
associated with reduced blood basophil
allergen response, but not with skin or
nasal mast cell allergen reactivity. This
was noted in an earlier study, but simul-
taneous measurements of blood basophil
allergen reactivity or parallel nasal aller-
gen reactivity were not performed (Ong
et al., 2005; Eckman et al., 2010). This
supports the conclusion that a reduction
in blood basophil allergen mediator
response is linked to the generation of
the skin late–phase response, but not in
the acute–phase skin reaction.
One explanation for the differences in
effects on the late–phase responses
between the nose and skin may be the
presence of chronic, baseline tissue
inflammation in the nose and not in the
skin (Ying et al., 2002; Fokkens et al.,
2012). In the absence of basal skin
inflammation in our subjects, the
acute–phase allergen skin response more
closely reflects a pure tissue mast cell
response and thus may not be altered in
the early weeks of omalizumab therapy.
This discordance between acute– and
late–phase shifts in allergen challenge
models in the nose and skin with oma-
lizumab treatment carries implications
for the interpretations of responses to
allergen in different tissue compartments.
Written informed consent was
obtained via a protocol approved by
the Johns Hopkins Hospital Institutional
Review Board and the National
Institute of Allergy and Infectious Dis-
eases’ Data Safety Monitoring Boards.
Declaration of Helsinki protocols were
followed. This study is registered with
ClinicalTrials.gov (registration number
NCT01003301). For the CONSORT
Flow Diagram, see the Supplementary
Material online.
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Figure 1. Acute- and late-phase changes in the nose and skin after 48 (omalizumab) and 65 (placebo)
days. The change from baseline (nasal allergen challenge (NAC)-1 minus NAC-2) after 48 days of
omalizumab treatment, or after 65 days of placebo, is displayed as scatter plots with the medians and
interquartile ranges (IQRs) for sneeze counts (upper panels) and intradermal flare size (mm) size (lower
panels). Omalizumab–treated subjects showed decreased acute–phase sneeze counts within group
(P¼ 0.01), but not when compared with placebo. No changes were seen in the late–phase sneeze counts.
Conversely, omalizumab–treated subjects’ intradermal skin tests showed no changes acutely, but
decreased significantly at 8 hours compared with placebo (P¼0.008). Skin flare size trended toward a
decrease at 24 hours.
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